Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,082 | -2,684 | -1,262 | -2,603 | -1,623 |
| Depreciation Amortization | 2,078 | 1,378 | 40 | 314 | 274 |
| Accounts receivable | N/A | N/A | 636 | -2,358 | -1,515 |
| Accounts payable and accrued liabilities | -590 | -316 | -187 | 404 | 143 |
| Other Working Capital | -576 | -366 | 432 | -1,984 | -1,374 |
| Other Operating Activity | 813 | 469 | -373 | 2,272 | 1,943 |
| Operating Cash Flow | $-2,357 | $-1,519 | $-714 | $-3,955 | $-2,152 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 142 | 142 |
| Debt Issued | 3,602 | 223 | N/A | N/A | N/A |
| Common Stock Issued | 3,058 | 3,058 | 3,058 | 5,524 | 5,524 |
| Other Financing Activity | 0 | 0 | 0 | -532 | -390 |
| Financing Cash Flow | $6,660 | $3,281 | $3,058 | $5,134 | $5,276 |
| Beginning Cash Position | 1,272 | 1,272 | 1,272 | 93 | 93 |
| End Cash Position | 5,575 | 3,034 | 3,616 | 1,272 | 3,217 |
| Net Cash Flow | $4,303 | $1,762 | $2,344 | $1,179 | $3,124 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,357 | -1,519 | -714 | -3,955 | -2,152 |
| Free Cash Flow | -2,357 | -1,519 | -714 | -3,955 | -2,152 |